Canadian Cancer Trials Group Bulletins


Recent Publications

HN.6 - A Phase III Study Of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab In Patients With Locally Advanced Stage III And IV Squamous Cell Carcinoma Of The Head And Neck

The purpose of this study was to determine whether progression-free survival (PFS) of patients with locoregionally advanced squamous cell carcinoma of the head and neck treated with accelerated-fractionation radiotherapy (RT) plus the anti-epidermal growth factor receptor antibody panitumumab is better than that of those treated with standard-fractionation RT plus high-dose cisplatin.

HN.6 was opened to accrual in December 2008 and randomized 320 patients. The study found that the two-year PFS of those receiving panitumumab plus accelerated-fractionation RT was not superior to that of those receiving cisplatin plus standard-fractionation RT; therefore, cisplatin plus standard-fractionation RT remains the standard of care for patients with locoregionally advanced squamous cell carcinoma of the head and neck.

An associated study compared quality of life and swallowing outcomes between arms and likewise found no clinically important differences 2-36 months post-treatment.

Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, Fitzgerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: A randomized clinical trial (ONLINE). JAMA Oncology 2016.

Ringash J, Waldron JN, Siu LL, Martino R, Winquist E, Wright JR, Nabid A, Hay JH, Hammond A, Sultanem K, Hotte S, Leong C, El-Gayed AAH, Naz F, Ramchandar K, Owen TE, Montenegro A, O'Sullivan B, Chen BE, Parulekar WR. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). Eur J Can 72: 192-9, 2017.

BR.24 - A Phase II/III Double Blind Randomized Trial of AZD2171 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce JP, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss GD, Leighl NB, Hung RJ, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman D. BRM Promoter Polymorphisms, Risk and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and NCIC CTG BR.24 trial (ONLINE). Clin Cancer Res 2016.

CO.17 - A Phase III Randomized Study of Cetuximab (Erbitux TM, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR) - Positive Colorectal Carcinoma

Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, Liu G. Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis (ONLINE). Pharmacogenomics J 2016.